ALKBH5 and neoplasm: Potential drugs such as CS1, CS2, and NSC48890, suggested for acute myeloid leukemia, and imidazobenzoxazin-5-thione (MV1035) aiming for tumor immunity target the inhibition of FTO and ALKBH5, respectively (Su et al. 2020; Tang et al. 2021).